Headlines about news affecting the Triangle from other publications:

  • News & Observer: Xerox cutting 53 jobs in Raleigh, brings total to 370 this year

Xerox is cutting more jobs in Raleigh.

“The layoffs will affect 49 pharmacists as well as one customer care assistant, one customer care team coach and one manager. Spokeswoman Coco Salazar said the employees provided “customer-care support in the form of answering pharmacy benefits questions” for a client who decided not to extend the contract and instead brought the function in-house,” The News and Observer reports.

Read more at:


  • ExitEvent: 18 startups that are hiring

“This month’s job list includes a mix of companies from around the Triangle, from foundations to job matching platforms to analytics software providers to brand new startups. The positions are just as diverse, including marketing, sales, management, engineering and development,” ExitEvent reports.

Read more at:


  • TBJ: Millennial workplace list includes Kimley-Horn

Kimley-Horn and Concord Hospitality, both based in Raleigh, crack Fortune’s ” 100 Best Workplaces for Millennials” list, but SAS (No. 9 in 2015) didn’t make it this year.

Reports The Triangle Business Journal:

“Kimley-Horn, which moved from Cary to Raleigh in March, made the list for the second time, ranking No. 3. In 2015, the company ranked No. 20. Raleigh-basedConcord Hospitality Enterprises made the list for the first time, ranking No. 84.”

Read more at:


  • TBJ: Chiesi USA could pay $742M for drug rights

Cary-based Chiesi USA has closed on its cardiovascular drug acquisition deal with The Medicines Company, reports the Triangle Business Journal:

“The deal was first announced in May, though new financial details have now been disclosed. The Medicines Company receives $262 million in cash at closing, and could receive up to $480 million in sales-based milestone and royalty payments.”

Read the details at:


  • Herald Sun: T3D gets nod for trial extension

Good news for a Triangle drug firm as reported in the Durham Herald Sun:

“T3D Therapeutics, Inc., a clinical stage drug development company targeting Alzheimer’s disease, announced that the U.S. Food and Drug Administration (FDA) has granted approval for a 26-week, open-label extension to its two-week Phase 2a clinical trial of T3D-959 in a limited number of subjects who completed the main Phase 2a study for the treatment of mild to moderate Alzheimer’s disease.”

Read more at: